Organization, visit our Web site at: Each of the above forward-looking statements is subject to changeīased on various important factors, including without limitation,Ĭompetitive actions in the marketplace and adverse actions of Government agencies, managed care organizations, hospitals, clinical National Genetics Institute, Inc., ViroMed Laboratories, Inc., TheĬenter for Esoteric Testing, DIANON Systems, Inc., US LABS, andĮsoterix and its Colorado Coagulation, Endocrine Sciences, andĬytometry Associates laboratories. Its expertise in innovative clinical testing technology with itsĬenters of Excellence: The Center for Molecular Biology and Pathology, Routine blood analyses to HIV and genomic testing. Than 220,000 clients, LabCorp offers clinical assays ranging from Of $3.6 billion in 2006, over 25,000 employees nationwide, and more Is a pioneer in commercializing new diagnostic technologies and theįirst in its industry to embrace genomic testing. Laboratory Corporation of America(R) Holdings, a S&P 500 company, Tests needed and potentially reduce the number of procedure-related This can help reduce the number of invasive "TheseĪdditional screening tools will allow physicians to offer patients aīroader range of tests for screening with higher detection rates and Services," said LabCorp's Executive Vice President, Chief Scientific Syndrome screening tests to our comprehensive menu of prenatal testing "LabCorp is pleased to add the Integrated and Sequential Down Translucency measurement, the highest Down syndrome detection ratesĪre achieved and fewer false-positives are experienced than withĬurrent first- or second-trimester screening. Sequential screening test results include a fetal ultrasound nuchal
#LABCORP SEQUENTIAL SCREENING LICENSE#
to license Intema's Integrated and Sequential Down syndrome LabCorp is the first full-service, national clinical laboratory in Patients should be offered testing that combines first- and ACOG's new recommendation states that, ideally, Regardless of age, all pregnant women should be offered screening forĭown syndrome. Gynecologists (ACOG) issued a Practice Bulletin recommending that, In January 2007, the American College of Obstetricians and Terms of the agreement were not disclosed. Second-trimester Down syndrome screening test results to assess the to license its technology for combining first- and LH), an industry leader in prenatal clinical laboratory testing,Īnnounced today that it has entered into an agreement with U.K. This can help reduce the number of invasive tests needed and potentially reduce the number of procedure-related pregnancy losses.PDF Version More Sensitive Technology Improves Assessment of Down Syndrome RiskBURLINGTON, N.C., (BUSINESS WIRE) - Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: "Adding these tools to our comprehensive menu of prenatal testing services will allow physicians to offer patients a broader range of screening tests with higher detection rates and low false positive rates. "LabCorp is pleased to be the first full-service, national clinical laboratory to license and make commercially available Integrated and Sequential Down syndrome screening technology," said LabCorp's Executive Vice President, Chief Scientific Officer and Medical Director, Myla P. to license its technology for combining first and second trimester Down syndrome screening test results. Subsequently, LabCorp announced an agreement with Intema, Ltd. In January 2007, the American College of Obstetricians and Gynecologists issued a Practice Bulletin recommending that regardless of age, all pregnant women be offered screening for Down syndrome, and ideally, be offered screening that combines first- and second-trimester screening. When Integrated screening and Sequential screening test results include a fetal ultrasound nuchal translucency measurement, the highest Down syndrome detection rates are achieved and fewer false positives are experienced than with current first- or second-trimester screening. Burlington, NC - Laboratory Corporation of America Holdings (LabCorp ) an industry leader in prenatal clinical laboratory testing, announced that it now offers Integrated screening and Sequential screening tests under license from Intema Limited.
0 kommentar(er)
